Cefditoren (sodium)

Cefditoren sodium (ME 1206) is a broad-spectrum, third-generation, oral cephalosporin antibacterial with enhanced stability against many common β lactamases. Cefditoren sodium has activity against Gram-negative organisms and Gram-positive organisms. Cefditoren sodium can be used in the research of infection diseases such as acute exacerbations of chronic bronchitis, community-acquired pneumonia (CAP), streptococcal pharyngitis/tonsillitis, or uncomplicated skin and skin structure infections^[1][2]. In Vitro: Cefditoren (sodium) shows good activity against pneumoniae, S. pyogenes, Staphylococcus aureus, H. influenzae and H. parainfluenzae, M. catarrhalis^[1].

Organism	MIC50 (mg/L)	MIC90 (mg/L)	susceptible (%)
Gram-positive organisms
Streptococcus pneumoniae (untyped)a	0.015-0.25	0.12-1
PS	≤0.008-0.03	0.015-0.25	99-100
PI	0.06-0.5	0.25-0.5	94-100
PR	0.25-1	0.5-2	7-100
S. pyogenes	≤0.008-0.03	0.015-0.03	100
Staphylococcus aureus (MS)	0.12-0.5	0.5-1	50-100
Gram-negative organisms
Haemophilus	≤0.008-≤0.03	0.015-0.13
influenzae (untyped)b
β-Lactamase +	≤0.008-0.03	0.015-0.06	100
β-Lactamase -	≤0.008-0.03	0.015-0.06	100
H. parainfluenzaeb	≤0.03	0.06
Moraxella	0.03-0.5	0.25-1	96
catarrhalis (untyped)b
β-Lactamase +	≤0.03-0.25	0.12-0.5	100
β-Lactamase -	≤0.008-0.03	0.015-0.06	100

^a Including PS, PI and PR strains.
^b Including both β-lactamase-positive and -negative strains.
MIC_50/90=mean minimum inhibitory concentrations required to inhibit the growth of 50% or 90% of bacterial strains; MS=susceptible to meticillin; PI=intermediate susceptibility to penicillin; PR=resistant to penicillin; PS=susceptible to penicillin. In Vivo: Pharmacokinetics in mice^[1]：

Cefditoren (mg/kg)	C0 (µg/ml)	t1/2 (h)	AUClast (µg× h/ml)	Tlast (h)
6.25	53.0	0.9	30.4	6
12.5	168.4	1.1	64.1	8
25	232.5	0.9	101.3	8
50	290.6	1.1	124.4	8